Deep targeted sequencing of circulating tumor DNA to inform treatment in patients with metastatic castration-resistant prostate cancer
Our study identifies known and novel prognostic and predictive biomarker candidates in patients with mCRPC undergoing first-line treatment with enzalutamide or abiraterone acetate. It further provides real-world evidence of the significant potential of genomic profiling of ctDNA to inform treatment in this setting. Clinical trials are warranted to advance the implementation of ctDNA-based biomarkers into clinical practice.
Authors
- Ea Marie Givskov Sørensen
- Henrik Grönberg (ORCID: https://orcid.org/0000-0002-1073-2753)
- Søren Vang (ORCID: https://orcid.org/0000-0002-1899-4205)
- Johan Lindberg (ORCID: https://orcid.org/0000-0003-3610-6774)
- Jacob Fredsøe (ORCID: https://orcid.org/0000-0002-7319-2467)
- Maria Rusan (ORCID: https://orcid.org/0000-0001-7798-2151)
- Bram De Laere (ORCID: https://orcid.org/0000-0002-1174-0384)
- Marianne Bjerre
- Maibritt Nørgaard (ORCID: https://orcid.org/0000-0002-9626-6510)
- Michael Borre (ORCID: https://orcid.org/0000-0002-1519-9185)
- Karina D. Sørensen (ORCID: https://orcid.org/0000-0002-4902-5490)
- Jørgen Bjerggaard Jensen (ORCID: https://orcid.org/0000-0002-4347-739X)
- Simone Weiss
- Karoline Kondrup (ORCID: https://orcid.org/0000-0003-0602-5981)
Institutions
- Aarhus University (DK)
- Glostrup Hospital (DK)
- Aarhus University Hospital (DK)
- Karolinska Institutet (SE)
- Ghent University (BE)
- Cancer Research Institute Ghent (BE)
Publication Details
- Journal
- Journal of Experimental & Clinical Cancer Research
- Published
- 2025-04-14
- DOI
- https://doi.org/10.1186/s13046-025-03356-0
- Citations
- 1
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 1.52
Funders
- Aarhus Universitet
- Aarhus Universitetshospital
- Kræftens Bekæmpelse
- Karolinska Institutet
- Novo Nordisk
- Snedkermester Sophus Jacobsen og Hustru Astrid Jacobsens Fond
- Region Midtjylland